Carbamazepine-phenprocoumon interaction.
Böttcher
T
T
University of Rostock, Department of Neurology, Germany.
Buchmann
J
J
Zettl
U K
UK
Benecke
R
R
D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000927:Anticonvulsants / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002220:Carbamazepine / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002544:Cerebral Infarction / Q000097:blood / Q000188:drug therapy*; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004789:Enzyme Activation / Q000187:drug effects; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008099:Liver / Q000201:enzymology; D008297:Male; D006899:Mixed Function Oxygenases / Q000097:blood; D010644:Phenprocoumon / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011517:Prothrombin Time
D000925:Anticoagulants; D000927:Anticonvulsants; D002220:Carbamazepine; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D010644:Phenprocoumon